News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

An Adaptive Two-Part Phase 2, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 Administered Once Monthly in Adult Subjects with Confirmed Non-Alcoholic Steatohepatitis

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To assess the effects of multiple ION224 doses when administered subcutaneously (SC) for 49 weeks (12 months) on NASH histologic improvement, i.e., proportion of subjects achieving at the End of the Treatment at least a 2-point reduction in NAFLD Activity Score (NAS), with at least 1-point improvement in hepatocellular ballooning or lobular inflammation, and without worsening in fibrosis stage.

Information: 

Principal Investigator
Fernando Membreno, MD
Sponsor
Ionis Pharmaceuticals
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram